It was however associated with the dose limiting toxicity of thrombocytopenia that was BCL-XL-mediated This is why the BCL-XL–sparing and BCL-2–selective inhibitor, VTC, was developed (88). This evidence concerns the gene BCL2L1 and Thrombocytopenia.